Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONSENSI is an oral tablet NDA approved by Purple Biotech in May 2018; the indication, mechanism of action, and pharmacologic class are not publicly disclosed in available data. Without clinical or mechanism details, the patient population and therapeutic role remain unspecified.
Peak11.9 years to LOE
Product is at peak lifecycle stage with minimal linked open positions (3 roles), suggesting a stable but small commercial footprint with limited near-term expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONSENSI has a very small and specialized job footprint (3 linked roles), concentrated in digital commercial and marketing functions. Career growth on this product is limited, making it better suited for entry-level or specialized digital marketing roles than traditional pharma career tracks.
SEO Marketing ManagerSocial Media (Working Student)
Worked on CONSENSI at Purple Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.